Trilacicilib
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parth Vikram Singh, MBBS[2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Trilacicilib is a kinase inhibitor that is FDA approved for the treatment of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.. Common adverse reactions include fatigue, hypocalcemia,hypokalemia,hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia..
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
COSELA is a kinase inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.
- COSELA is for intravenous use only.
- The recommended dose of COSELA is 240 mg/m2 as a 30-minute intravenous infusion completed no more than 4 hours prior to the start of chemotherapy on each day chemotherapy is administered.
- Reduce dose in patients with moderate or severe hepatic impairment.
- See Full Prescribing Information for instructions on preparation and administration.
- DOSAGE FORMS AND STRENGTHS
For injection: 300 mg of trilaciclib as a lyophilized cake in a single-dose vial.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Trilacicilib in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Trilacicilib in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Trilacicilib FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Trilacicilib in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Trilacicilib in pediatric patients.
Contraindications
- COSELA is contraindicated in patients with a history of serious hypersensitivity reactions to trilaciclib. Reactions have included anaphylaxis
Warnings
Injection-Site Reactions, Including Phlebitis and Thrombophlebitis
- COSELA administration can cause injection-site reactions including phlebitis and thrombophlebitis. Injection-site reactions including phlebitis and thrombophlebitis occurred in 56 (21%) of 272 patients receiving COSELA in clinical trials, including Grade 2 (10%) and Grade 3 (0.4%) adverse reactions (ARs). The median time to onset from start of COSELA was 15 days (range 1 to 542) and from the preceding dose of COSELA was 1 day (1 to 15).The median duration was 1 day (range 1 to 151 for the resolved cases). Injection-site reactions including phlebitis and thrombophlebitis resolved in 49 (88%) of the 56 patients and led to discontinuation of treatment in 3 (1%) of the 272 patients.
- Monitor patients for signs and symptoms of injection-site reactions, phlebitis, and thrombophlebitis, including infusion-site pain and erythema during infusion. For mild (Grade 1) to moderate (Grade 2) injection-site reactions, flush line/cannula with at least 20 mL of sterile 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP after end of infusion. For severe (Grade 3) or life-threatening (Grade 4) injection-site reactions, stop infusion and permanently discontinue COSELA.
Acute Drug Hypersensitivity Reactions
- COSELA administration can cause acute drug hypersensitivity reactions, including facial edema and urticaria. Acute drug hypersensitivity reactions occurred in 16 (6%) of 272 patients receiving COSELA in clinical trials, including Grade 2 reactions (2%). One patient experienced a Grade 2 anaphylactic reaction 4 days after receiving COSELA, which resolved with epinephrine, and treatment with COSELA was continued. The median time to onset from start of COSELA was 77 days (range 2 to 256) and from the preceding dose of COSELA was 1 day (range 1 to 28). The median duration was 6 days (range 1 to 69 for the resolved cases). Acute drug hypersensitivity reactions resolved in 12 (75%) of the 16 patients.
- Monitor patients for signs and symptoms of acute drug hypersensitivity reactions including facial, eye, and tongue edema, urticaria, pruritus, and anaphylactic reactions. For moderate (Grade 2) acute drug hypersensitivity reactions, stop infusion and hold COSELA until the adverse reaction recovers to Grade ≤1. For severe (Grade 3) or life-threatening (Grade 4) acute drug hypersensitivity reactions, stop infusion and permanently discontinue COSELA [see Dosage and Administration (2.2)].
Interstitial Lung Disease/Pneumonitis
- Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with cyclin-dependent kinases (CDK)4/6 inhibitors, the same drug class as COSELA. ILD/pneumonitis occurred in 1 (0.4%) of 272 patients receiving COSELA in clinical trials. The adverse reaction was Grade 3 and reported 2 months after discontinuing COSELA, in a patient receiving a confounding medication. The adverse reaction did not resolve.
- Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis such as cough, dyspnea, and hypoxia. For recurrent moderate (Grade 2) ILD/pneumonitis, permanently discontinue COSELA. For severe (Grade 3) or life-threatening (Grade 4) ILD/pneumonitis, permanently discontinue COSELA.
Embryo-Fetal Toxicity
Based on its mechanism of action, COSELA can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should use an effective method of contraception during treatment with COSELA and for at least 3 weeks after the final dose.
Adverse Reactions
Clinical Trials Experience
The following clinically significant adverse reactions are described elsewhere in the label:
- Injection-Site Reactions, including phlebitis and thrombophlebitis.
- Acute Drug Hypersensitivity Reactions.
- ILD/Pneumonitis.
Clinical Trials Experience
- Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
- The safety of COSELA was evaluated in Studies 1, 2, and 3. Patients received COSELA 240 mg/m2 by 30-minute intravenous infusion prior to chemotherapy on each chemotherapy day. The data described in this section reflect exposure to COSELA among 240 patients (122 patients in the trilaciclib group and 118 patients in the placebo group) being treated for extensive stage-small cell lung cancer (ES-SCLC) in 3 randomized, double-blind, placebo-controlled trials: 32 patients with treatment naïve ES-SCLC received carboplatin (AUC 5 Day 1) + etoposide (100 mg/m2 Days 1-3) every 21 days; 58 received carboplatin (AUC 5 Day 1) + etoposide (100 mg/m2 Days 1-3) every 21 days + atezolizumab (1200 mg on Day 1) every 21 days; 32 patients with previously treated ES-SCLC received topotecan (1.5 mg/m2 Days 1-5) every 21 days.
Study 1: COSELA Prior to Etoposide, Carboplatin, and Atezolizumab (E/P/A)
Patients with newly diagnosed ES-SCLC not previously treated with chemotherapy
- Study 1 (G1T28-05; NCT03041311) was an international, randomized (1:1), double-blind, placebo-controlled study of COSELA or placebo administered prior to treatment with etoposide, carboplatin, and atezolizumab (E/P/A) for patients with newly diagnosed ES-SCLC not previously treated with chemotherapy. The data presented below are for the 105 patients who received study treatment.
- Eighty-five percent of patients receiving COSELA and 91% receiving placebo completed 4 cycles of induction therapy.
Study 2: COSELA Prior to Etoposide and Carboplatin (E/P)
Patients with newly diagnosed ES-SCLC not previously treated with chemotherapy
- Study 2 (G1T28-02; NCT02499770) was an international, randomized (1:1), double-blind, placebo-controlled study of COSELA or placebo administered prior to treatment with etoposide and carboplatin (E/P) for patients with newly diagnosed ES-SCLC not previously treated with chemotherapy. The data presented below are for the 75 patients who received study treatment.
- Seventy-six percent of patients in the COSELA group and 87% of patients in the placebo group completed at least 4 cycles of therapy. The median duration of treatment was 6 cycles in each treatment group.
Study 3: COSELA Prior to Topotecan
Patients with ES-SCLC previously treated with chemotherapy
- Study 3 (G1T28-03; NCT02514447) was an international, randomized (2:1), double-blind, placebo-controlled study of COSELA or placebo administered prior to treatment with topotecan for patients with ES-SCLC previously treated with chemotherapy. The data presented below are for the 60 patients who received study treatment with the 1.5 mg/m2 dose of topotecan.
- Thirty-eight percent of patients receiving COSELA and 29% of patients receiving placebo completed 5 or more cycles of therapy. The median duration of treatment was 3 cycles in each treatment group.
Integrated Safety Analysis
- The adverse reaction summary presented in TABLE 3 are pooled safety results from Studies 1, 2, and 3. The patients included in the pooling are those randomized patients that received at least 1 dose of COSELA (122 patients) or placebo (118 patients).
Seventy-one percent of patients receiving COSELA and 78% of patients receiving placebo completed at least 4 cycles of therapy. The median duration of treatment was the same (4 cycles) for patients receiving COSELA and placebo.
- Serious adverse reactions occurred in 30% of patients receiving COSELA. Serious adverse reactions reported in >3% of patients who received COSELA included respiratory failure, hemorrhage, and thrombosis.
- Permanent discontinuation due to an adverse reaction occurred in 9% of patients who received COSELA. Adverse reactions leading to permanent discontinuation of any study treatment for patients receiving COSELA included pneumonia (2%), asthenia (2%), injection-site reaction, thrombocytopenia, cerebrovascular accident, ischemic stroke, infusion-related reaction, respiratory failure, and myositis (<1% each).
- Fatal adverse reactions were observed in 5% of patients receiving COSELA. Fatal adverse reactions for patients receiving COSELA included pneumonia (2%), respiratory failure (2%), acute respiratory failure (<1%), hemoptysis (<1%), and cerebrovascular accident (<1%).
- Infusion interruptions due to an adverse reaction occurred in 4.1% of patients who received COSELA.
- The most common adverse reactions (≥10%) were fatigue, hypocalcemia, hypokalemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia. The most frequently reported Grade ≥3 adverse reaction (≥5%) in patients receiving COSELA occurring at the same or higher incidence than in patients receiving placebo was hypophosphatemia.
- The most common adverse reactions reported in at least 5% of patients receiving COSELA with a ≥2% higher incidence compared to patients receiving placebo are shown in TABLE 3.
Adverse Reactions in ≥5% Patients with SCLC Receiving COSELA (with ≥2% Higher Incidence in COSELA Compared to Placebo)included neutropenia (32% and 69%), febrile neutropenia (3% and 9%), anemia (16% and 34%), thrombocytopenia (18% and 33%), leukopenia (4% and 17%), and lymphopenia (<1% and <1%), respectively.
Postmarketing Experience
There is limited information regarding Trilacicilib Postmarketing Experience in the drug label.
Drug Interactions
Effect of COSELA on Other Drugs, Certain OCT2, MATE1, and MATE-2K Substrates
- COSELA is an inhibitor of OCT2, MATE1, and MATE-2K. Co-administration of COSELA may increase the concentration or net accumulation of OCT2, MATE1, and MATE-2K substrates in the kidney (e.g., dofetilide, dalfampridine, and cisplatin).
Refer to the prescribing information for these concomitant medications for assessing the benefit and risk of concomitant use of COSELA.
Use in Specific Populations
Pregnancy
Risk Summary
- Based on the mechanism of action, COSELA can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12)]. There are no available human or animal data on COSELA use to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women of the potential risk to a fetus.
- The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. However, the background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies in the United States general population.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Trilacicilib in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Trilacicilib during labor and delivery.
Nursing Mothers
Risk Summary
- There are no data on the presence of trilaciclib in either human or animal milk, the effects on the breastfed child or the effects on milk production. Because of the potential for serious adverse reactions in breastfed children, advise lactating women to not breastfeed while taking COSELA and for at least 3 weeks after the last dose.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
Geriatic Use
- In the pooled efficacy dataset from Studies 1, 2, and 3, 46% of 123 patients randomized to COSELA were ≥65 years of age, and 49% of 119 patients randomized to placebo were ≥65 years of age. No overall differences in safety or effectiveness of COSELA were observed between these patients and younger patients.
Gender
There is no FDA guidance on the use of Trilacicilib with respect to specific gender populations.
Race
There is no FDA guidance on the use of Trilacicilib with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Trilacicilib in patients with renal impairment.
Hepatic Impairment
- Reduce the dose of COSELA to 170 mg/m2 in patients with moderate or severe hepatic impairment (Child-Pugh classes B and C). No dose adjustment is required in patients with mild hepatic impairment (Child-Pugh class A).
- Trilaciclib is mainly metabolized in the liver. Trilaciclib exposure increased with moderate and severe hepatic impairment (Child-Pugh classes B and C)
Females of Reproductive Potential and Males
Pregnancy Testing
- Based on its mechanism of action, COSELA can cause fetal harm if administered to a pregnant woman.
Pregnancy testing is recommended for females of reproductive potential prior to initiating COSELA.
Contraception
- COSELA can cause fetal harm when administered to pregnant women.
- Advise female patients of reproductive potential to use effective contraception during treatment with COSELA and for at least 3 weeks after the final dose.
Infertility
- No studies have been performed in humans to evaluate the effects of COSELA on fertility in either sex.
- Based on animal toxicology studies, COSELA may impair fertility in females of reproductive potential.
Immunocompromised Patients
There is no FDA guidance one the use of Trilacicilib in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Trilacicilib Administration in the drug label.
Monitoring
There is limited information regarding Trilacicilib Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Trilacicilib and IV administrations.
Overdosage
There is limited information regarding Trilacicilib overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Trilacicilib Pharmacology in the drug label.
Mechanism of Action
Trilaciclib is a transient inhibitor of CDK 4 and 6. Hematopoietic stem and progenitor cells (HSPCs) in the bone marrow give rise to circulating neutrophils, RBCs, and platelets. HSPC proliferation is dependent on CDK4/6 activity.
Structure
COSELA for injection contains trilaciclib dihydrochloride, a kinase inhibitor. The chemical name for trilaciclib is 2'- { [ 5- ( 4-methylpiperazin-1-yl ) pyridin-2-yl]amino } -7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino [ 1',2':1,5]pyrrolo[2,3-d]pyrimidin ] -6'-one. Trilaciclib dihydrochloride is a water-soluble yellow solid, with molecular formula of C24H30N8O•2HCl, a molecular weight of 519.48 g/mol ( Free base: 446.56 g/mol), and the following chemical structure:
COSELA ( trilaciclib ) for injection is a sterile, preservative-free, yellow lyophilized cake in a single-dose vial for intravenous infusion after reconstitution and dilution. Each single-dose vial contains the equivalent of 300 mg of trilaciclib ( provided as 349 mg of trilaciclib dihydrochloride ) and the following inactive ingredients: citric acid monohydrate ( 75.6 mg ) and mannitol ( 300 mg ) ; hydrochloric acid and sodium hydroxide to adjust pH.
Pharmacodynamics
Bone Marrow
- Trilaciclib exhibited dose-dependent inhibition of CD45+/CD3+ lymphocyte proliferation following administration of single-dose COSELA 96 or 192 mg/m2 (0.4 or 0.8 times the approved recommended dose) in healthy subjects.
- Trilaciclib increased the percentage of cells arrested in G1 up to 32 hours post-infusion for all bone marrow progenitor subsets evaluated (hematopoietic stem cell/multipotent progenitor, oligopotent progenitor, monocyte lineage, granulocyte lineage, erythroid lineage, and megakaryocyte lineage) following a single dose of COSELA 192 mg/m2 (0.8 times the approved recommended dose) in healthy subjects. Partial recovery of the total bone marrow with resumption of proliferation of the bone marrow progenitor subsets was observed by 32 hours post-dose. This transient G1 arrest of hematopoietic stem cells contributed to the myeloprotective effect of trilaciclib.
Cardiac Electrophysiology
- COSELA is associated with dose-dependent and delayed increase in the QTc interval. The underlying mechanism of the delayed QT effect is unknown.
- At the clinical dose of 240 mg/m2, COSELA did not have a clinically relevant effect on QTc (i.e., >10 msec). QTc prolongation was observed at higher doses.
Pharmacokinetics
- The maximum concentration (Cmax) increased proportionally whereas the total plasma exposure (AUC0-last) increased slightly greater than proportional over a dosage range of trilaciclib 200 mg/m2 to 700 mg/m2 (0.83 to 2.9 times the approved recommended dose). There was no accumulation of trilaciclib following repeated dosing.
Distribution
- The in vitro human plasma protein binding of trilaciclib is 69% and appeared independent of trilaciclib concentration from 0.75 to 3.0 μg/mL. The blood/plasma ratio ranged from 1.21 to 1.53 for trilaciclib across concentrations of 0.5 μg/mL to 50 μg/mL in vitro. The volume of distribution at steady state was 1130 L.
Elimination
- The mean terminal half-life of trilaciclib is approximately 14 hours. Clearance was estimated to be 158 L/hr.
Metabolism
Trilaciclib undergoes extensive metabolism. Trilaciclib is the predominant circulating compound in plasma following intravenous administration, representing ~50% of plasma total radioactivity. In vitro studies indicated that trilaciclib is primarily metabolized by aldehyde oxidase (AO), cytochrome P450 (CYP) 3A4 and CYP2C8.
Excretion
- After a single dose of radiolabeled trilaciclib 192 mg/m2 (0.8 times the approved recommended dosage), approximately 79.1% of the dose was recovered in feces (7% unchanged) and 14% was recovered in urine (2% unchanged).
- Trilaciclib is eliminated mainly via the fecal route, with a small contribution of the renal route.
Specific Populations
No clinically significant differences in the pharmacokinetics of trilaciclib were observed based on age (range: 19 to 80 years), sex, race, mild to moderate renal impairment (30 to 89 mL/min/1.73 m2 measured by estimated glomerular filtration rate [eGFR]), or mild hepatic impairment (total bilirubin ≤ULN and AST >ULN, or total bilirubin >1.0 to 1.5 × ULN, irrespective of AST). The effect of severe renal impairment (<30 mL/min/1.73 m2), end stage renal disease, or dialysis on trilaciclib pharmacokinetics has not been studied.
Subjects with Hepatic Impairment
Trilaciclib unbound AUCinf increased by 40% and 63%, respectively, in subjects with moderate and severe hepatic impairment (Child-Pugh classes B and C). No clinically significant differences were observed in trilaciclib systemic exposures in subjects with mild hepatic impairment.
Drug Interaction Studies
- Clinical Studies
- Cytochrome P450 (CYP) Enzymes: There were no clinically significant differences in trilaciclib pharmacokinetics when used concomitantly with itraconazole (strong CYP3A inhibitor) or rifampin (strong CYP3A inducer). There were no clinically significant differences in midazolam (CYP3A substrate) pharmacokinetics when used concomitantly with trilaciclib.
- Transporter Systems: Concomitant use of trilaciclib increased metformin (OCT2, MATE1, and MATE-2K substrate) AUCinf and Cmax by approximately 65% and 81%, respectively. Renal clearance of metformin was decreased by 37%. There were no clinically significant differences in topotecan (MATE1 and MATE-2K substrate) pharmacokinetics when used concomitantly with trilaciclib.
In Vitro Studies
- CYP Enzymes: Trilaciclib did not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6. Trilaciclib is an inducer for CYP1A2, and is not an inducer for CYP2B6 or CYP3A4.
Transporter Systems: Trilaciclib did not inhibit P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OAT1, or OAT3. Trilaciclib was a substrate of BCRP and P-gp, but not bile salt export pump (BSEP), MATE1, MATE-2K, or OCT.
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment of Fertility
- Carcinogenesis studies have not been conducted with trilaciclib.
- Trilaciclib was negative for mutagenic potential in a bacterial reverse mutation (Ames) assay and negative for clastogenic potential in an in vitro histone H2AX phosphorylation assay in primary human fibroblasts. Trilaciclib increased the frequency of micronucleus formation in human lymphocytes in vitro. Clastogenic potential of trilaciclib was not assessed in vivo.
- Fertility studies have not been performed to evaluate the effects of trilaciclib. Treatment with trilaciclib in female rats and dogs resulted in reductions in mean ovary and uterus weights at clinically relevant exposures, which were reversible after a two-week drug-free recovery period.
Clinical Studies
- The efficacy of COSELA was established in three randomized, double-blind, placebo-controlled trials in patients with extensive stage-small cell lung cancer (ES-SCLC). Study 1 (G1T28-05; NCT03041311) enrolled adult patients receiving carboplatin, etoposide, and atezolizumab for newly diagnosed ES-SCLC. Study 2 (G1T28-02; NCT02499770) enrolled adult patients receiving etoposide/carboplatin for newly diagnosed ES-SCLC. Study 3 (G1T28-03; NCT02514447) enrolled adult patients receiving topotecan for previously treated ES-SCLC.
- During Cycle 1, all three studies prohibited primary prophylactic granulocyte-colony stimulating factor (G-CSF) and erythropoiesis-stimulating agent (ESA) use. Both ESAs and prophylactic G-CSF were allowed from Cycle 2 onwards as clinically indicated. Therapeutic G-CSF, RBC, and platelet transfusions were allowed at any time during the studies as clinically indicated.
Study 1: COSELA Prior to Etoposide, Carboplatin, and Atezolizumab (E/P/A)
Patients with newly diagnosed ES-SCLC not previously treated with chemotherapy
- Study 1 (G1T28-05) was a randomized (1:1), double-blind, placebo-controlled study of COSELA or placebo administered prior to treatment with etoposide, carboplatin, and atezolizumab (E/P/A) for patients with newly diagnosed ES-SCLC not previously treated with chemotherapy.
- A total of 107 patients were randomized to receive COSELA (n=54) or placebo (n=53) prior to administration of E/P/A; patients were stratified by Eastern Cooperative Oncology Group (ECOG) performance status (0 to 1 vs 2) and the presence of brain metastases. Carboplatin (AUC 5) and atezolizumab (1200 mg) were administered on Day 1 and etoposide (100 mg/m2) and COSELA (240 mg/m2) or placebo were administered on Days 1, 2, and 3 of a 21-day cycle for a maximum of 4 cycles (induction). After induction, maintenance atezolizumab (1200 mg) monotherapy on Day 1 of a 21-day cycle continued until disease progression or unacceptable toxicity. COSELA was not administered during maintenance.
- The study population characteristics were: median age 64 years (range: 45 to 83); 70% male; 97% white; 14% ECOG performance status 2; 28% with a history of brain metastases; 38% current smokers; 46% lactate dehydrogenase (LDH) >ULN.
- The mean relative dose intensities (RDIs) for E/P/A in patients receiving COSELA were 93%, 95%, and 93%, respectively. The mean RDIs for E/P/A in patients receiving placebo were 88%, 89%, and 91%, respectively. Dose reductions of carboplatin occurred in 2% of patients receiving COSELA and in 25% of patients receiving placebo; dose reductions of etoposide occurred in 6% of patients receiving COSELA and in 26% of patients receiving placebo. No dose reduction was allowed for COSELA or atezolizumab.
- The study demonstrated a statistically significantly shorter duration of severe neutropenia (DSN) in Cycle 1 (0 vs 4 days) and a lower proportion of patients with severe neutropenia (SN) (2% vs 49%) in patients receiving COSELA compared with placebo (TABLE 5).
Nineteen percent of patients receiving COSELA had Grade 3 or 4 decreased hemoglobin compared with 28% of patients receiving placebo (adjusted relative risk 0.663 [95% CI: 0.336, 1.310]). The rate of RBC transfusions over time was 1.7/100 weeks for patients receiving COSELA and 2.6/100 weeks for patients receiving placebo (adjusted relative risk was not estimable). Six percent of patients receiving COSELA received erythropoiesis-stimulating agents (ESAs) compared with 11% of patients receiving placebo (adjusted relative risk 0.529 [95% CI: 0.145, 1.927]).
- ANCOVA=analysis of covariance; CI=confidence interval; DSN=duration of severe neutropenia; G-CSF=granulocyte colony-stimulating factor; N=total number of patients in each treatment group; RBC=red blood cell; SD=standard deviation.
- The following statistical models were used to assess treatment effects: non-parametric ANCOVA (DSN in Cycle 1); modified Poisson regression (occurrence of SN and RBC transfusion on/after 5 weeks); negative binomial regression (number of all-cause dose reductions). All models included the following as covariates: ECOG status, presence of brain metastases, and the corresponding baseline laboratory values.
- One-sided adjusted p-value obtained from a Hochberg-based gatekeeping procedure.
Study 2: COSELA Prior to Etoposide and Carboplatin
Patients with newly diagnosed ES-SCLC not previously treated with chemotherapy
- Study 2 (G1T28-02) was a randomized (1:1), double-blind, placebo-controlled evaluation of COSELA or placebo administered prior to treatment with etoposide and carboplatin (E/P) for patients with newly diagnosed ES-SCLC not previously treated with chemotherapy. A total of 77 patients were randomized to COSELA (n=39) or placebo (n=38) and stratified by ECOG performance status (0 to 1 vs 2). Carboplatin (AUC 5) was administered on Day 1 and etoposide (100 mg/m2) and COSELA (240 mg/m2) or placebo were administered on Days 1, 2, and 3 of a 21-day cycle until disease progression or unacceptable toxicity.
- Ten percent of patients receiving COSELA had Grade 3 or 4 decreased hemoglobin compared with 18% of patients receiving placebo. The rate of RBC transfusions over time was 0.5/100 weeks for patients receiving COSELA and 1.9/100 weeks for patients receiving placebo. Three percent of patients receiving COSELA received ESAs compared with 5% of patients receiving placebo.
- DSN=duration of severe neutropenia; G-CSF=granulocyte colony-stimulating factor; N=total number of patients in each treatment group; RBC=red blood cell; SD=standard deviation.
Study 3: COSELA Prior to Topotecan
Patients with ES-SCLC previously treated with chemotherapy
- Study 3 (G1T28-03) included a randomized, double-blind, placebo-controlled evaluation of COSELA or placebo administered prior to topotecan in patients with ES-SCLC previously treated with chemotherapy. A total of 61 patients were randomized to COSELA (n=32) or placebo (n=29). Patients were stratified by ECOG performance status (0 to 1 vs 2) and sensitivity to first-line treatment. Topotecan (1.5 mg/m2) and COSELA (240 mg/m2) or placebo were administered on Days 1-5 of a 21-day cycle. Treatment was administered until disease progression or unacceptable toxicity.
- Thirty-eight percent of patients receiving COSELA had Grade 3 or 4 decreased hemoglobin compared with 59% of patients receiving placebo. The rate of RBC transfusions over time was 2.6/100 weeks for patients receiving COSELA and 6.3/100 weeks for patients receiving placebo. Three percent of patients receiving COSELA received ESAs compared with 21% of patients receiving placebo.
DSN=duration of severe neutropenia; G-CSF=granulocyte colony-stimulating factor; N=total number of patients in each treatment group; RBC=red blood cell; SD=standard deviation.
Patient Subgroups
- Treatment efficacy was examined across different subgroups, including those quantifying the risk of febrile neutropenia, anemia, and RBC transfusions; results were consistent across subgroups.
How Supplied
COSELA (trilaciclib) for injection is a yellow lyophilized cake supplied in a single-dose vial. Each carton (NDC 73462-101-01) contains one 300 mg strength single-dose vial.
Storage
- Store COSELA vials at 20°C to 25°C (68°F to 77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
- The vial stopper is not made with natural rubber latex.
Images
Drug Images
{{#ask: Page Name::Trilacicilib |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Trilacicilib |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
Injection-Site Reactions, Including Phlebitis and Thrombophlebitis
- Inform patients of the signs and symptoms of injection-site reactions, including phlebitis and thrombophlebitis. Advise patients to contact their healthcare provider immediately for signs and symptoms of injection-site reactions, including phlebitis and thrombophlebitis.
Acute Drug Hypersensitivity Reactions
- Advise patients to contact their healthcare provider immediately for signs and symptoms of acute drug hypersensitivity reactions including facial, eye, and tongue edema, urticaria, pruritis, and anaphylactic reactions.
Interstitial Lung Disease/Pneumonitis
- Advise patients to immediately report new or worsening respiratory symptoms.
Embryo-Fetal Toxicity
- Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy.
- Advise females of reproductive potential to use effective contraception during treatment with COSELA and for at least 3 weeks after the final dose.
Lactation
- Advise women not to breastfeed during treatment with COSELA and for at least 3 weeks after the final dose of COSELA .
Drug Interactions
- Advise patients to inform their healthcare providers of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products.
Precautions with Alcohol
Alcohol-Trilacicilib interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
COSELA
Look-Alike Drug Names
There is limited information regarding Trilacicilib Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.